Ovarian cystectomy in the treatment of apparent early-stage immature teratoma

Zhao, Ting; Liu, Yan; Xiao, Wang; Zhang, Hao; Lu, Yuan

doi:10.1177/0300060517692149

Cited by 13 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 1994, D. M. O'Connor and H. J. Norris identified the tumour grade as one of the most important risk factors for relapse in these patients (30), showing a recurrence rate of 70% in grade 3 disease and 18% in grade 2 disease. A significant association between grade and risk of recurrence is extensively reported in the literature (30)(31)(32), further confirmed by Pashankar et al (27) and Zhao et al (33).…”

Section: Results In the Context Of Published Literaturementioning

confidence: 53%

Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy

Marino,

Grassi,

De Ponti

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveImmature teratomas are rare malignant ovarian germ cell tumours, typically diagnosed in young women, where fertility-sparing surgery is the treatment of choice. The role of adjuvant chemotherapy in stage I disease remains controversial. We evaluated the impact of surveillance versus chemotherapy on the recurrence rate in stage I immature teratomas.MethodsWe collected a single centre retrospective series of patients with stage I immature teratomas treated with fertility-sparing surgery at San Gerardo Hospital, Monza, Italy, between 1980 and 2019. Potential risk factors for recurrence were investigated by multivariate logistic regression.ResultsOf the 74 patients included, 12% (9/74) received chemotherapy, while 88% (65/74) underwent surveillance. Median follow-up was 188 months. No difference in recurrence was found in stage IA/IB and IC immature teratomas [10% (6/60) vs. 28.6% (4/14) (P=0.087)], grade 1, grade 2, and grade 3 [7.1% (2/28) vs. 14.3% (4/28) vs. 22.2% (4/18) (p=0.39)], and surveillance versus chemotherapy groups [13.9% (9/65) vs. 11.1% (1/9)) (p = 1.00)]. In univariate analysis, the postoperative approach had no impact on recurrence. The 5-year disease-free survival was 87% and 90% in the surveillance and chemotherapy groups, respectively; the overall survival was 100% in both cohorts.ConclusionsOur results support the feasibility of surveillance in stage I immature teratomas. Adjuvant chemotherapy may be reserved for relapses. However, the potential benefit of chemotherapy should be discussed, especially for high-risk tumours. Prospective series are warranted to confirm our findings.What is already known on this topicTo date, no consensus has been reached regarding the role of adjuvant chemotherapy in stage I immature teratomas of the ovary. Some studies suggest that only surveillance is an acceptable choice. However, guidelines are not conclusive on this topic.What this study addsNo difference in terms of recurrence was observed between the surveillance and the adjuvant chemotherapy group. All patients who relapsed were successfully cured with no disease-related deaths.How this study might affect research, practice or policyAdjuvant chemotherapy should be appropriately discussed with patients. However, it may be reserved for relapse according to our data.

show abstract

Section: Results In the Context Of Published Literaturementioning

confidence: 53%

Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy

Marino,

Grassi,

De Ponti

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer can be grouped by cellular origin, including epithelial cells (ovarian carcinoma), stromal cells (ovarian adenoma), and germ cells (ovarian teratoma and teratocarcinoma) 1 . Ovarian teratocarcinoma mainly consists of various layers of differentiated cells and embryonal carcinoma stem cells 2 . The main current management of ovarian teratocarcinoma is surgery in combination with chemotherapeutics 3 .…”

Section: Introductionmentioning

confidence: 99%

Luteolin Suppresses Teratoma Cell Growth and Induces Cell Apoptosis via Inhibiting Bcl-2

Yan³

et al. 2019

oncol res

View full text Add to dashboard Cite

Luteolin, which is found in plant foods, has a range of therapeutic applications. In order to examine the potential roles of luteolin in ovarian teratocarcinoma, the human ovarian teratocarcinoma cell line PA-1 was selected for functional experiments in vitro and in vivo. We demonstrated that luteolin inhibited the proliferation and colony formation of PA-1 cells in vitro. The flow cytometry results suggested that luteolin induced apoptosis of PA-1 cells in a dose-dependent manner. Immunofluorescence and qRT-PCR results showed that the expression of B-cell lymphoma-2 (Bcl-2) was decreased in luteolin-treated cells, whereas the expression of Bcl-2-associated X (Bax) was increased compared with that in the control group. In addition, luteolin inhibited the tumor growth of ovarian teratocarcinoma cells in a xenograft model. All the results suggested that luteolin induced cell apoptosis and inhibited tumor growth of PA-1 cells.

show abstract